Postscripts Rx

Prices that used to hide in the shadows are stepping into the light—and it’s changing how patients get their medicines. We dive deep into the PBM reckoning: why scrutiny is mounting, how California’s new law opens the books on rebates and reimbursements, and what more than 30 states signal for the future of drug access. From there, we chart the path pharma is taking to meet the moment—standing up direct-to-consumer channels, publis...

A pharmaceutical giant just pressed the D2C button—and the ripple effects could reset how Americans find, pay for, and receive their medications. We unpack Pfizer’s move to list discounted drugs on TrumpRX, why visible pricing matters to patients skipping doses due to cost, and how a retail-like experience collides with the realities of safety, compliance, and payer rules. The story isn’t just about cheaper price tags; it’s about w...

The pharmaceutical landscape is undergoing a seismic shift as the Trump administration drops a bombshell 100% tariff on imported branded and patented drugs, effective October 1st. This game-changing policy mandates that pharmaceutical companies build manufacturing plants on American soil or face potentially devastating market consequences.

We dive deep into the multifaceted implications of this dramatic policy shift that h...

Policy sparks the shift, but patients feel the impact—faster access, steadier supply, and smarter support. We dig into why major pharma players are pouring billions into U.S. manufacturing, how most favored nation pricing is reshaping reimbursement strategy, and where digital medication tools close the gap between a written script and a successful outcome. With examples like Eli Lilly’s Texas investment and Pfizer’s recent pricing ...

Pharmaceutical giants are bringing manufacturing back to American soil in a massive strategic pivot. Eli Lilly's recent $6.5 billion investment in a Texas facility for its obesity medications signals a transformative shift that's rapidly spreading throughout the industry, with Pfizer, Amgen, and Novo Nordisk collectively announcing over $20 billion in domestic manufacturing projects.

This reshoring revolution isn...

Curious about where healthcare marketing is heading in the age of AI? Kait Tuson, Founder and CEO of Hello Helio, shares invaluable insights on navigating the complex intersection of technology, regulation, and patient care with Ryan Janvion of Medisafe.

The conversation begins with a candid look at AI adoption in healthcare—not just the hype, but the practical realities. While AI has become "table stakes" in the...

Pharmaceutical marketing stands at a critical turning point following the FDA and HHS's September 2025 coordinated crackdown on direct-to-consumer prescription drug advertising. This watershed moment marks an unprecedented shift in enforcement, with regulators issuing approximately  enforcement actions—including warning letters to industry giants like Eli Lilly, Novo Nordisk, and telehealth providers.

The heart of thi...

The future of pharmaceutical marketing and patient engagement is undergoing a profound transformation. While omnichannel strategies have long been considered the gold standard, promising seamless experiences across all platforms, they've often devolved into inefficient "scattergun" approaches that prioritize presence over performance.

This episode explores the evolution from traditional omnichannel to what i...

Navigating the evolving landscape of pharmaceutical patient support requires staying ahead of emerging technologies and industry trends. In this illuminating conversation with Cathy Zaremba from Medisafe's Marketing team, we dive into key takeaways from two major industry conferences—Hubs West and Fierce Pharma Week—where changing regulations, digital innovation, and artificial intelligence dominated discussions.

The ...

Television networks have developed a dangerous dependency on pharmaceutical advertising dollars, creating a precarious financial ecosystem that few outside the industry fully comprehend. Drug makers poured nearly $3.73 billion into national TV advertising during just the first eight months of 2025—representing 14% of all television ad spending in America. When projected forward, pharma's annual TV investment will exceed $5 bil...

A seismic shift is underway at the FDA that could fundamentally alter how drugs reach American patients. Recent reporting reveals the agency is dramatically scaling back its use of independent advisory committees—consulting external experts on just 3% of medications this year, down from the historical 20-50%. This quiet revolution prioritizes efficiency but raises profound questions about transparency and public trust.

At ...

The pharmaceutical landscape in America is undergoing a transformation unlike anything we've seen before. When the revised Most Favored Nation (MFN) drug pricing policy dropped in May 2025, few anticipated the tidal wave of strategic responses it would trigger. Today, we're examining how this policy bombshell has catalyzed over $277 billion in confirmed pharmaceutical investments across the United States.

What be...

Pharmaceutical giants are abandoning the United Kingdom, and it's sending shockwaves through global healthcare markets. When industry leaders call a major market "uninvestable," every executive needs to pay attention.

The stark reality is unmistakable. Pfizer, AbbVie, Lilly, and Novartis are all scaling back their UK presence due to punitive pricing structures, rigid reimbursement frameworks, and frustrating...

The pharmaceutical advertising landscape stands at a crossroads as bold new regulatory initiatives threaten to upend decades of established marketing practices. This week, the administration announced plans directing the FDA to reconsider the 30-year-old guidelines that have enabled the modern era of direct-to-consumer pharmaceutical advertising.

At stake is a 1997 policy change that revolutionized pharmaceutical marketing...

A seismic shift is underway in pharmaceutical marketing regulation. Yesterday, the FDA fired a warning shot heard across the industry, announcing a massive crackdown on what they're calling misleading pharmaceutical advertising. With over 3,500 letters sent to manufacturers, this unprecedented enforcement action targets violations across all channels—traditional media, digital platforms, and especially social media influencer ...

The pharmaceutical landscape is transforming before our eyes as drug manufacturers respond to the Biden administration's May 2023 Most Favored Nation (MFN) pricing executive order with unprecedented domestic investment. This watershed moment has triggered nearly $250 billion in committed capital expenditures as the industry's largest players rush to secure their American footprint.

AstraZeneca leads with a stagge...

A quick chat with Medisafe's Ryan Janvion, Stacey Wasserman and Cathy Zaremba on what to expect at Fierce Pharma Week 2025. Industry leaders discuss how hyper-personalization sets true patient engagement apart from the buzzwords that saturate the pharmaceutical industry.

• Excitement about sharing Medisafe's new updates with conference attendees
• The significance of behavioral intervention technology in crea...

A seismic shift is underway in pharmaceutical manufacturing. The FDA's newly unveiled Advanced Manufacturing Technologies Designation Program promises to accelerate reviews for facilities producing drugs and biologics on American soil—potentially slashing approval timelines by up to 40%. With pharmaceutical giants already committing over $20 billion to new domestic production facilities, this represents far more than a regulat...

Regulatory timelines are changing dramatically, and pharmaceutical companies must adapt or risk being left behind. The Biden administration's pressure on the FDA is yielding concrete results - approval processes that once took 10-12 months are now being completed in about half the time through expedited review pathways.

This acceleration isn't hypothetical. A recent Reuters investigation revealed how the White Ho...